NASDAQ · GDTC
CytoMed Therapeutics Limited financials
$0.8890−3.89%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Gross margin | — | — | — |
| Operating income | — | — | — |
| Net income | — | — | — |
| Net margin | — | — | — |
| Diluted EPS | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — |
| Free cash flow | — | — | — |
| Diluted shares | 11.6M | 11.5M | 10.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $1.6M | $3.7M | $6.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $318.3K | $317.8K | $334.7K |
| Total assets | $6.2M | $7.4M | $9.4M |
| Total liabilities | $879.2K | $753.2K | $852.4K |
| Shareholders' equity | $5.3M | $6.7M | $8.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology